+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

TNF Alpha Inhibitors Market By Drug Class (Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab), By Pipeline Analysis (Phase I, Phase II, Phase III), By Regions - Global Forecast up to 2025

  • ID: 4846886
  • Report
  • August 2019
  • Region: Global
  • 140 pages
  • Infoholic Research LLP
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

1 of 3

FEATURED COMPANIES

  • 3SBIO Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Apogenix
  • Celgene Corporation
  • Celltrion Healthcare
  • MORE
This market research report includes a detailed segmentation of the global TNF alpha inhibitors market by drug class (adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab), pipeline analysis (phase I, phase II, and phase III), and regions (North America, Europe, Asia Pacific, and Rest of the World).

Overview of the Global TNF Alpha Inhibitors Market Research:
The author's market research report predicts that the global TNF alpha inhibitors market will grow at a CAGR of 3.6% during the forecast period 2019–2025. TNF inhibitors, also known as TNF blockers, anti-TNF drugs, and biologic therapies, are a cluster of medications used to treat inflammatory conditions, including rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease (Crohn’s and ulcerative colitis), and psoriasis. The drugs decrease inflammation and can stop disease development by targeting an inflammation-causing substance, tumor necrosis factor (TNF).

The market is witnessing the loss of patents in Europe for various blockbuster drugs, resulting in the emergence of biosimilars. In April 2019, Eticovo – a biosimilar from Samsung Bioepis to Amgen’s Enbrel (etanercept), received FDA approval. In November 2018, FDA approved Hyrimoz developed by Sandoz, a biosimilar to AbbVie’s blockbuster drug Humira, which will be launched in the US market by 2023. Currently, only five approved TNF inhibitors, i.e., adalimumab, certolizumab, etanercept, golimumab, and infliximab, control the market. The wide application of these drugs for numerous autoimmune diseases ensures constant growth of the market during the forecast period 2019–2025.

Key players operating in this field, i.e., AbbVie Inc., Amgen Inc., Johnson & Johnson, and Celgene Corporation, are generating the majority of the revenue in the global TNF alpha inhibitors market.

According to the author analysis, North America accounted for the largest share of the global TNF alpha inhibitors market in 2018 and will retain a high position during the forecast period. North America is followed by Europe, with a market share of more than 20% in 2018.

By Drug Class:
  • Adalimumab
  • Certolizumab Pegol
  • Etanercept
  • Golimumab
  • Infliximab
In 2018, the adalimumab segment accounted for the largest share and is expected to grow at a mid-single-digit CAGR during the forecast period. Increased clinical efficacy and high preference by physicians for the treatment of severe rheumatic diseases made the segment the largest shareholder in 2018. Golimumab is expected to grow at a high CAGR during the forecast period 2019–2025.

Pipeline Analysis:
  • Phase I
  • Phase II
  • Phase III
Many companies are making huge investments to develop products and enter the market as soon as biologics lose their patents. Among various TNF alpha inhibitors, adalimumab has the highest number of ongoing clinical trials, followed by certolizumab pegol.

By Regions:
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
Based on geography, North America dominated the market in 2018 with a market share of over 60% and is expected to maintain this position during the forecast period. Europe is projected to grow at a high CAGR during the forecast period. The increasing acceptance of biosimilars and increasing investments in the R&D of new drugs make Europe the fastest-growing region during the forecast period.

Global TNF Alpha Inhibitors Market Research Competitive Analysis: The market is growing at a steady rate, i.e., at a CAGR of 3.6% during the forecast period 2019–2025. New drug launches, product approvals, strategic partnerships, and collaborations are among the significant strategies adopted by market leaders to maintain their leadership position. For instance, in July 2019, the US FDA approved HADLIMA by Samsung Bioepis, a biosimilar referencing HUMIRA, to treat juvenile idiopathic arthritis, adult Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, rheumatoid arthritis, and plaque psoriasis. In March 2019, the US FDA approved Cimzia injection to treat non-radiographic axial spondyloarthritis (nr-axSpA) in adults, with detached signs of swelling making it the first-ever FDA approved treatment fulfilling the unmet needs for nr-axSpA; and in May 2018, the drug was approved for the treatment of moderate-to-severe plaque psoriasis.

The rising incidence of chronic autoimmune diseases has led to the increasing launch of biosimilars globally. In May 2019, Fresenius Kabi launched biosimilar adalimumab IDACIO in Germany. In May 2019, Janssen launched Simponi Autoinjector in Japan, and the drugs are distributed by Mitsubishi Tanabe. In addition, other leading vendors are focusing on hugely investing in R&D activities to develop new drugs to obtain a high share in the market.

Key Vendors:
  • AbbVie Inc.
  • Novartis AG
  • Amgen Inc.
  • Johnson & Johnson
  • Celgene Corporation
  • Celltrion Healthcare
  • Samsung Bioepis Co. Ltd.
  • Apogenix
  • 3SBIO Inc.
  • Shanghai CP Guojian Pharmaceutical Co. Ltd.
Key Competitive Facts:
  • UCB Biopharma S.P.R.L. is conducting a phase 3 clinical trial in 15 centers in Germany to study “Efficacy and safety of certolizumab pegol (CZP) versus active comparator and placebo in subjects with Plaque Psoriasis (PSO) (CIMPACT)”.
  • Globally, over 95% of the clinical trials of certolizumab are conducted by UCB Pharma.
  • In July 2018, Mylan made a patent license agreement with AbbVie over Mylan’s proposed Humira biosimilar. Under the terms of the agreement, AbbVie will grant Mylan exclusive licenses on Humira’s intellectual properties on July 31, 2023 in the US and other countries excluding Europe.
Benefits
The report provides complete details about the sub-segment of the global TNF alpha inhibitors market. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the pharmaceuticals segment in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.

Key Takeaways:
  • Understanding the potential market opportunity with precise market size and forecast data.
  • Detailed market analysis focusing on the growth of TNF alpha inhibitors industry.
  • Factors influencing the growth of the TNF alpha inhibitors market.
  • In-depth competitive analysis of dominant and pure-play vendors.
  • Prediction analysis of the TNF alpha inhibitors industry in both developed and developing regions.
  • Key insights related to major segments of the TNF alpha inhibitors market.
  • Latest market trend analysis impacting the buying behavior of the consumers.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 3SBIO Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Apogenix
  • Celgene Corporation
  • Celltrion Healthcare
  • MORE
1 Industry Outlook
1.1 Industry Overview
1.1.1 Global Driver for Pharmaceutical Demand
1.1.2 R&D Pipeline in Pharmaceutical Industry
1.1.3 Top Pharma Drugs by Sales ($Million)
1.2 Industry Trends
1.3 Total Addressable Market
1.4 Trends of the Immunotherapy Drugs Market

2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Trends of the TNF Alpha Inhibitors Market
3.4 Related Markets
3.4.1 Oncology Drugs
3.4.2 Biologics
3.4.3 Biosimilars

4 Market Outlook
4.1 Market Segmentation
4.2 PEST Analysis
4.3 Porter 5(Five) Forces

5 Market Characteristics
5.1 DRO – Global TNF Alpha Inhibitors Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing prevalence of chronic autoimmune disease
5.1.1.2 Constant research to develop target-based biologics
5.1.2 Opportunities
5.1.2.1 Continuous development of biosimilars
5.1.2.2 Increasing opportunities in the emerging market
5.1.3 Restraints
5.1.3.1 Complex drug development process
5.1.3.2 Patent expiry
5.2 DRO – Impact Analysis
5.3 Key Stakeholders

6 Product: Market Size and Analysis
6.1 Overview
6.2 Adalimumab
6.3 Certolizumab Pegol
6.4 Etanercept
6.5 Golimumab
6.6 Infliximab

7 Pipeline Analysis: Market Size and Analysis
7.1 Overview
7.2 Phase I
7.3 Phase II
7.4 Phase III

8 Regions: Market Size and Analysis
8.1 Overview
8.2 North America
8.2.1 Overview
8.2.2 US
8.2.3 Canada and Others
8.3 Europe
8.3.1 Overview
8.3.2 UK
8.3.3 Germany
8.3.4 Russia and Ukraine
8.3.5 Turkey
8.4 Asia Pacific
8.4.1 Overview
8.4.2 India
8.4.3 Pakistan
8.4.4 Indonesia
8.4.5 Thailand
8.5 Rest of the World
8.5.1 Overview
8.5.2 Mexico
8.5.3 Brazil
8.5.4 Middle East and Africa

9 Competitive Landscape

10 Vendors Profile
10.1 AbbVie Inc.
10.1.1 Overview
10.1.2 Geographic Revenue
10.1.3 Business Focus
10.1.4 SWOT Analysis
10.1.5 Business Strategies
10.2 Novartis AG
10.2.1 Overview
10.2.2 Business Units
10.2.3 Geographic Revenue
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategies
10.3 Amgen Inc.
10.3.1 Overview
10.3.2 Geographic Revenue
10.3.3 Business Focus
10.3.4 SWOT Analysis
10.3.5 Business Strategies
10.4 Johnson & Johnson
10.4.1 Overview
10.4.2 Business Units
10.4.3 Geographic Revenue
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategies
10.5 Celgene Corporation
10.5.1 Overview
10.5.2 Geographic Revenue
10.5.3 Business Focus
10.5.4 SWOT Analysis
10.5.5 Business Strategies

11 Companies to Watch For
11.1 Apogenix
11.1.1 Overview
11.2 Celltrion Healthcare
11.2.1 Overview
11.3 Samsung Bioepis Co. Ltd.
11.3.1 Overview
11.4 3SBio Inc.
11.4.1 Overview
11.5 Shanghai CP Guojian Pharmaceutical Co. Ltd.
11.5.1 Overview

List of Tables
  • Drug Class And Their Fda Approved Indications
  • Global Tnf Alpha Inhibitor Market Revenue, By Product, 2018–2025 ($Million)
  • Drug Overview: Adalimumab
  • Biosimilars And Non-Originator Biologicals Of Adalimumab Approved Or In Development
  • Drug Overview: Certolizumab Pegol
  • Biosimilars And Non-Originator Biologicals Of Certolizumab Pegol In Development
  • Drug Overview: Etanercept
  • Biosimilars And Non-Originator Biologicals Of Etanercept Approved Or In Development
  • Drug Overview: Golimumab
  • Drug Overview: Infliximab
  • Biosimilars And Non-Originator Biologicals Of Infliximab In Development
  • Molecules In Pipeline In Phase I
  • Molecules In Pipeline In Phase Ii
  • Molecules In Pipeline In Phase Iii
  • Global Tnf Alpha Inhibitors Drugs Market Revenue, By Geography, 2018–2025($Million)
  • Abbvie Inc.: Offerings
  • Abbvie Inc.: Recent Developments
  • Novartis Ag: Offerings
  • Novartis Ag: Recent Developments
  • Amgen Inc.: Offerings
  • Amgen Inc.: Recent Developments
  • Johnson & Johnson: Product Offerings
  • Johnson & Johnson: Recent Developments
  • Celgene Corporation: Offerings
  • Celgene Corporation: Recent Developments
  • Apogenix: Snapshot
  • Apogenix: Recent Developments
  • Celltrion Healthcare: Snapshot
  • Celltrion Healthcare: Recent Developments
  • Samsung Bioepis Co. Ltd.: Snapshot
  • Samsung Bioepis Co. Ltd.: Recent Developments
  • 3Sbio Inc.: Snapshot
  • 3Sbio Inc.: Recent Developments
  • Shanghai Cp Guojian Pharmaceutical Co. Ltd.: Snapshot
List of Charts
  • Global Pharmaceutical R&D Spending (2010–2017)
  • Pharmaceutical Drugs By Sales, 2018
  • Research Methodology Of Global Tnf Alpha Inhibitors Market
  • Global Tnf Alpha Inhibitors Market Revenue, 2018–2025 ($Million)
  • Segmentation Of Global Tnf Alpha Inhibitors Market
  • Pest Analysis Of Global Tnf Alpha Inhibitors Market
  • Porter 5 Forces On Global Tnf Alpha Inhibitors Market
  • Market Dynamics – Dro Analysis
  • Dro – Impact Analysis Of Global Tnf Alpha Inhibitors Market
  • Key Stakeholders
  • Humira Annual Revenue, 2011–2018 ($Million)
  • Adalimumab Drugs Market Revenue, 2018–2025 ($Million)
  • Pipeline Analysis Of Adalimumab
  • Cimzia Annual Revenue, 2011–2018 ($Million)
  • Certolizumab Pegol Market Revenue, 2018–2025 ($Million)
  • Pipeline Analysis Of Certolizumab Pegol
  • Etanercept Drugs Market Revenue, 2018–2025 ($Million)
  • Pipeline Analysis Of Etanercept
  • Golimumab Drugs Market Revenue, 2018–2025 ($Million)
  • Pipeline Analysis Of Golimumab
  • Infliximab Drugs Market Revenue, 2018–2025 ($Million)
  • Pipeline Analysis Of Infliximab
  • Global Tnf Alpha Inhibitor Drugs Pipeline
  • Molecules In Phase I
  • Molecules In Phase II
  • Molecules In Phase III
  • Global Tnf Alpha Inhibitors Drugs Market Share By Regional Segmentation, 2018 (%)
  • Tnf Alpha Inhibitors Drugs Market Revenue In North America, 2018–2025 ($Million)
  • Adalimumab North America Market Revenue, 2018–2025 ($Million)
  • Adalimumab North America Market Revenue, By Country 2018 (% Share)
  • Certolizumab Pegol North America Market Revenue, 2018–2025 ($Million)
  • Certolizumab Pegol North America Market Revenue, By Country 2018 (% Share)
  • Etanercept North America Market Revenue, 2018–2025 ($Million)
  • Etanercept North America Market Revenue, By Country 2018 (% Share)
  • Golimumab North America Market Revenue, 2018–2025 ($Million)
  • Golimumab North America Market Revenue, By Country 2018 (% Share)
  • Infliximab North America Market Revenue, 2018–2025 ($Million)
  • Infliximab North America Market Revenue, By Country 2018 (% Share)
  • Adalimumab Market Revenue In Us, 2018–2025 ($Million)
  • Certolizumab Pegol Market Revenue In Us, 2018–2025 ($Million)
  • Etanercept Market Revenue In Us, 2018–2025 ($Million)
  • Golimumab North America Market Revenue, 2018–2025 ($Million)
  • Infliximab North America Market Revenue, 2018–2025 ($Million)
  • Tnf Alpha Inhibitors Drugs Market Revenue In Europe, 2018–2025 ($Million)
  • Adalimumab Europe Market Revenue, 2018–2025 ($Million)
  • Adalimumab Europe Market Revenue, By Country 2018 (% Share)
  • Certolizumab Pegol Europe Market Revenue, 2018–2025 ($Million)
  • Certolizumab Pegol Europe Market Revenue, By Country 2018 (% Share)
  • Etanercept Europe Market Revenue, 2018–2025 ($Million)
  • Etanercept Europe Market Revenue, By Country 2018 (% Share)
  • Golimumab Europe Market Revenue, 2018–2025 ($Million)
  • Golimumab Europe Market Revenue, By Country 2018 (% Share)
  • Infliximab Europe Market Revenue, 2018–2025 ($Million)
  • Infliximab Europe Market Revenue, By Country 2018 (% Share)
  • Tnf Alpha Inhibitors Drugs Market Revenue In Asia Pacific, 2018–2025 ($Million)
  • Adalimumab Asia Pacific Market Revenue, 2018–2025 ($Million)
  • Adalimumab Asia Pacific Market Revenue, By Country 2018 (% Share)
  • Certolizumab Pegol Asia Pacific Market Revenue, 2018–2025 ($Million)
  • Certolizumab Pegol Asia Pacific Market Revenue, By Country 2018 (% Share)
  • Etanercept Asia Pacific Market Revenue, 2018–2025 ($Million)
  • Etanercept Asia Pacific Market Revenue, By Country 2018 (% Share)
  • Golimumab Asia Pacific Market Revenue, 2018–2025 ($Million)
  • Golimumab Asia Pacific Market Revenue, By Country 2018 (% Share)
  • Infliximab Asia Pacific Market Revenue, 2018–2025 ($Million)
  • Infliximab Asia Pacific Market Revenue, By Country 2018 (% Share)
  • Tnf Alpha Inhibitors Drugs Market Revenue In Rest Of The World, 2018–2025 ($Million)
  • Adalimumab Row Market Revenue, 2018–2025 ($Million)
  • Adalimumab Row Market Revenue, By Country 2018 (% Share)
  • Certolizumab Pegol Row Market Revenue, 2018–2025 ($Million)
  • Certolizumab Pegol Row Market Revenue, By Country 2018 (% Share)
  • Etanercept Row Market Revenue, 2018–2025 ($Million)
  • Etanercept Row Market Revenue, By Country 2018 (% Share)
  • Golimumab Row Market Revenue, 2018–2025 ($Million)
  • Golimumab Row Market Revenue, By Country 2018 (% Share)
  • Infliximab Row Market Revenue, 2018–2025 ($Million)
  • Infliximab Row Market Revenue, By Country 2018 (% Share)
  • Annual Treatment Cost
  • Abbvie Inc.: Overview Snapshot
  • Abbvie Inc.: Geographic Revenue
  • Abbvie Inc.: Swot Analysis
  • Novartis Ag: Overview Snapshot
  • Novartis Ag: Business Units
  • Novartis Ag: Geographic Revenue
  • Novartis Ag: Swot Analysis
  • Amgen Inc.: Overview Snapshot
  • Amgen Inc.: Geographic Revenue
  • Amgen Inc.: Swot Analysis
  • Johnson & Johnson: Overview Snapshot
  • Johnson & Johnson: Business Units
  • Johnson & Johnson: Geographic Revenue
  • Johnson & Johnson: Swot Analysis
  • Celgene Corporation: Overview Snapshot
  • Celgene Corporation: Geographic Revenue
  • Celgene Corporation: Swot Analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc.
  • Novartis AG
  • Amgen Inc.
  • Johnson & Johnson
  • Celgene Corporation
  • Celltrion Healthcare
  • Samsung Bioepis Co. Ltd.
  • Apogenix
  • 3SBIO Inc.
  • Shanghai CP Guojian Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll